2017-10-10
2016-11-08
Welcome to DIREKT
DIREKT - Disarming the intravascular innate immune response to improve treatment modalities for chronic kidney disease
DIREKT is a EU funded FP7 project headed by professor Bo Nilsson at Uppsala University, Sweden, in collaboration with leading professors, physicians, researchers, CEOs and business developers within the fields of immunology, chemistry and biotechnology.
The DIREKT project is focusing on the chronic kidney disease known as end-stage renal disease (ESRD), which is affecting millions of patients worldwide. These patients require long-term treatment of hemodialysis that could be discontinued after kidney transplantation but still with great risks of delayed graft function and organ failure. The scientific work of the DIREKT partners aims to dampen the immune reactions and reduce side effects during treatment to the benefit for kidney patients.
The participants of the Kidney DIREKT project
